证券代码：688617 证券简称：惠泰医疗 公告编号：2026-013 深圳惠泰医疗器械股份有限公司 关于 2025 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发人民币现金红利 10 元（含税），不进行资 本公积转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣除股份回购专 户中股份数量后的股份总数为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，公司拟维持每 股分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 公司未触及《上海证券交易所科创板股票上市规则》（以下简称《科创 板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警 示的情形。 本次利润分配预案已经公司第三届董事会第四次会议审议通过，尚需提 交公司 2025 年年度股东会审议。 一、利润分配预案的内容 （一）利润分配预案的具体内容 经立信会计师事务所（特殊普通合伙）审计，截至 2025 ...

Group 1 - The core point of the news is the performance of the Science and Technology Innovation Pharmaceutical ETF (工银, 588860), which opened with a gain of 0.48% at 0.626 yuan on March 24 [1][2] - The ETF's major holdings showed positive movements, with notable increases including Zai Lab (泽璟制药) up 2.81%, BeiGene (百济神州) up 1.90%, and Honor Bio (荣昌生物) up 2.70% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, managed by ICBC Credit Suisse Asset Management Company, with a return of 24.70% since its inception on August 8, 2024, and a recent one-month return of -10.90% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for the stocks mentioned [3]

Summary of China Medtech Sector Updates Industry Overview - The China Medtech sector faced multiple challenges in 2025, with the market size remaining largely flat at +0.4% YoY in the first three quarters of 2025 [8][6]. - Domestic companies experienced a revenue change of +7.6% in consumables, +0.8% in equipment, and -14.5% in IVD segments for 9M25 [8][6]. Key Insights Equipment Market - Hospital equipment procurement showed a recovery in 2025, with tender value up 13% YoY, particularly in ultrasound and gastrointestinal endoscopes, which grew by 42% and 40% YoY respectively [13][6]. - However, the growth rate slowed significantly in the latter half of 2025, with a decline of -3% YoY from July to November compared to +35% YoY in the first half [13][6]. - Local government bond issuance for healthcare decreased by 36% YoY, indicating reduced funding for healthcare projects [18][6]. Consumables Market - The high-value consumables market was stable, with a growth of +0.2% YoY in 9M25. Notable growth was seen in non-vascular interventional products (+8% YoY) and neurosurgery products (+5% YoY) [23][6]. - The implementation of Value-Based Procurement (VBP) is expected to cover 61% of the high-value consumables market by 2026, up from 58% in 2025 [28][6]. IVD Market - The IVD market faced negative impacts from policy changes, with a 9% YoY decline in core lab tests in 9M25. Immunoassay and clinical chemistry tests saw declines of 14% and 11% YoY respectively [33][6]. - The reagent price pressures are expected to continue, affecting the overall market outlook for 2026 [33][6]. Company Updates Mindray (300760.SZ) - Projected revenue growth of 6.5% in 2026, with a focus on overseas expansion [67][6]. - Anticipated challenges include a potential decline in domestic revenue due to pricing pressures [67][6]. United Imaging (688271.SH) - Expected revenue growth of 25% in 2026, with a strong emphasis on overseas sales expansion [66][6]. - The company is positioned well for market share gains and manageable policy impacts in China [66][6]. Yuyue Medical (002223.SZ) - Projected revenue growth of 13% in 2026, with multiple product approvals expected to drive performance [66][6]. Global Companies' Performance - GE Healthcare reported an 11% revenue decline YoY in China, while Siemens Healthineers saw a 5% decline [39][6]. - Abbott and Danaher also faced challenges due to China's healthcare pricing reforms, impacting their revenue outlook [39][6]. Procurement Dynamics - The total tender value for hospital equipment procurement rose 9% YoY in 2025, but growth is expected to stabilize at a more sustainable rate [40][6]. - Import substitution trends are evident, with local companies gaining market share in various equipment categories [40][6]. Conclusion - The China Medtech sector is navigating a complex landscape with mixed performance across different segments. While there are signs of recovery in certain areas, ongoing pricing pressures and policy changes pose significant challenges for both domestic and global companies. The outlook for 2026 remains cautious, with expectations of modest growth in procurement volumes and potential revenue declines due to price cuts.

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-009 深圳惠泰医疗器械股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2026/2/10，由公司董事会提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2026 2 9 | 月 | 日~2026 | 年 | 12 | 日 8 | | 预计回购金额 | 1.5亿元~2亿元 | | | | | | | 回购价格上限 | 315元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 853,702股 | | | | | | | 实际回购股数占总股本比例 | 0.61% | | | | | | | 实际回购金额 ...

Investment Rating - The report provides a positive investment outlook for the electrophysiology industry, highlighting significant growth potential driven by increasing patient numbers and technological advancements in treatment methods [11][21]. Core Insights - The electrophysiology market is expected to expand significantly, with the global market projected to reach $79 billion by 2025 and $201 billion by 2034, reflecting a CAGR of 11.0%. In China, the market is anticipated to grow from ¥157 billion in 2025 to ¥420 billion by 2032, with a CAGR of 15.1% [21][22]. - The report emphasizes the increasing prevalence of rapid arrhythmias, with an estimated 28.2 million patients in China by 2024, driving demand for catheter ablation procedures as the first-line treatment [16][21]. - Domestic companies are making strides in the electrophysiology market, with significant room for growth in market share as they innovate and develop new technologies [22][40]. Market Overview - The report outlines the current state of the electrophysiology market, noting that the demand for electrophysiology procedures is increasing due to the aging population and the rising incidence of rapid arrhythmias [21][22]. - The report identifies key players in the electrophysiology market, including Johnson & Johnson, Boston Scientific, and Abbott, which dominate the market share in various product categories [22][23]. Technological Advancements - Innovations in electrophysiology devices, such as three-dimensional mapping systems and high-density mapping catheters, are expected to enhance procedural efficiency and patient outcomes [21][27]. - The report discusses the development of new technologies, including AI-assisted mapping and integrated mapping and ablation systems, which are set to transform the treatment landscape [27][39]. Competitive Landscape - The competitive landscape is characterized by a mix of established international players and emerging domestic companies, with the latter gradually increasing their market presence through technological advancements and product innovations [22][40]. - The report highlights the importance of regulatory approvals for new products, noting that the pace of approvals has been increasing, particularly for domestic companies [30][39].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides various investment recommendations for specific companies within the sector. Core Insights - The report highlights the rapid growth of the electrophysiology industry, driven by an increasing number of patients with rapid arrhythmias and advancements in medical technology. The market for electrophysiology devices is expected to expand significantly due to rising demand and improved penetration rates of innovative products [11][21]. Summary by Sections Market Overview - The global electrophysiology device market is projected to grow from $7.9 billion in 2025 to $20.1 billion by 2034, with a CAGR of 11.0%. In China, the market is expected to increase from ¥15.7 billion in 2025 to ¥42 billion by 2032, with a CAGR of 15.1% [21][22]. Key Industry Trends - The report identifies several key trends in the electrophysiology market: 1. Increasing prevalence of rapid arrhythmias, with an estimated 28.2 million patients in China by 2024 [16]. 2. The adoption of catheter ablation as the first-line treatment for rapid arrhythmias due to its effectiveness and minimal invasiveness [16]. 3. The ongoing shift towards domestic production in the electrophysiology device market, with local companies making significant technological advancements [22]. Company Recommendations - The report suggests focusing on specific companies within the electrophysiology sector: 1. For electrophysiology mapping products, companies like 惠泰医疗 (Huitai Medical), 微电生理 (Micro Electrophysiology), and 锦江电子 (Jinjiang Electronics) are highlighted for their innovative technologies and market potential [22]. 2. In the radiofrequency ablation segment, major players include Johnson & Johnson, Abbott, and Medtronic, with a focus on their advanced product offerings [30]. 3. The report also emphasizes the potential of pulse field ablation (PFA) technology, with companies like 锦江电子 (Jinjiang Electronics) leading in this area [39]. Technological Innovations - The report discusses several technological advancements in the electrophysiology field: 1. The introduction of AI-assisted mapping and ablation technologies that enhance procedural efficiency and accuracy [27]. 2. The development of multi-modal integration techniques that combine mapping, ablation, and verification in a single catheter [39]. 3. Innovations in cryoablation and radiofrequency systems that improve patient safety and treatment outcomes [36][30]. Regulatory Landscape - The report notes that the approval process for electrophysiology devices has seen a slowdown in recent years, but the proportion of domestic products has been increasing, indicating a shift towards local manufacturing and innovation [27][36].

关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688617 证券简称：惠泰医疗 公告编号：2026-008 深圳惠泰医疗器械股份有限公司 （www.sse.com.cn）披露的《深圳惠泰医疗器械股份有限公司关于以集中竞价交易 方式回购股份方案暨回购报告书》（公告编号：2026-004）。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做 出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 | 回购方案首次披露日 | 2026/2/10，由公司董事会提议 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2026 2 9 12 8 | 日~2026 | 年 | 日 | | 预计回购金额 | 1.5亿元~2亿元 | | | | ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The medical consumables sector saw a 1.94% increase last week, with the sector's performance being relatively stable compared to other healthcare segments [4][12] - The current PE ratio for the medical consumables sector is 36.85X, which has increased by 0.68X from the previous week, while the PB ratio stands at 2.66X [5][20] - Key companies in the sector, such as Huatai Medical and Sainuo Medical, reported significant revenue growth, indicating a positive trend in the industry [6][23] Summary by Sections Industry Performance - The medical consumables sector reported a closing index of 6047.08 points, reflecting a 1.94% increase [4] - Over the past month, the sector has shown a relative return of 2%, while the absolute return over the last 12 months is 18% [3][4] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 36.85X, with a one-year maximum of 40.1X and a minimum of 28.88X [5][17] - The PB ratio is at 2.66X, with a one-year maximum of 2.92X and a minimum of 2.13X [20] Industry Dynamics and Company Announcements - Huatai Medical reported a revenue of 258,392.73 million yuan for 2025, a 25.08% increase year-on-year, with a net profit of 82,063.66 million yuan, up 21.91% [6][22] - Sainuo Medical achieved a total revenue of 52,540.79 million yuan, a 14.53% increase year-on-year, with a net profit of 4,728.63 million yuan, reflecting a significant growth of 3,057.05% [6][23] Investment Recommendations - The report suggests focusing on high-value consumables companies that are showing performance reversals and have strong innovation capabilities, such as Huatai Medical and Microneurophysiology [7][26] - The report emphasizes the importance of companies that can control costs and innovate in a competitive environment, particularly in the orthopedic consumables sector [7][26]

Summary of Huatai Medical's Earnings Call Company Overview - **Company**: Huatai Medical - **Fiscal Year**: 2025 Key Financial Metrics - **Revenue**: - 2025 revenue reached 2.584 billion CNY, representing a year-over-year increase of 25.1% [1] - **Net Profit**: - Net profit attributable to shareholders was 821 million CNY, up 21.9% year-over-year [1] - **Net Profit (Excluding Non-recurring Items)**: - Net profit excluding non-recurring items was 791 million CNY, reflecting a 23.0% increase year-over-year [1] - **Quarterly Performance (Q4 2025)**: - Q4 revenue was 716 million CNY, a year-over-year increase of 32.4% and a quarter-over-quarter increase of 9.6% [1] - Q4 net profit attributable to shareholders was 197 million CNY, up 36.1% year-over-year but down 0.4% quarter-over-quarter [1] - Q4 net profit (excluding non-recurring items) was 189 million CNY, showing a year-over-year increase of 39.9% but a quarter-over-quarter decrease of 1.4% [1] Profitability Ratios - **Net Profit Margin**: - The net profit margin for Q4 was 27.5%, an increase of 0.74 percentage points year-over-year but a decrease of 2.77 percentage points quarter-over-quarter [2] - The net profit margin (excluding non-recurring items) was 26.3%, up 1.41 percentage points year-over-year but down 2.95 percentage points quarter-over-quarter [2] Operational Insights - **Market Expansion**: - The company has been actively deepening market development through various promotional activities, leveraging R&D, technology, quality, and market channels to enhance product coverage and admission rates [3] - **Cost Control**: - Emphasis on cost management with R&D and sales expenses focused on core products like PFA, clinical validation, and next-generation product development [3] - Achieved synergy between net profit and revenue through refined operations and optimized expenditure structure [3] Additional Notes - The company's performance aligns with prior forecasts, which anticipated revenue growth of 20-30% and net profit growth (both attributable and excluding non-recurring items) of 15-25% [1]

Market Overview - A-shares concluded February with the Shanghai Composite Index achieving three consecutive monthly gains, and daily trading volumes exceeding 1 trillion yuan have become the norm [1][20] - On February 27, the three major indices showed mixed results, with over 3,200 stocks rising and a total trading volume of 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1][20] Sector Performance - The small metals sector surged, with rare earth prices continuing to rise, leading to a wave of limit-up stocks including Hunan Gold [21][23] - The chemical sector also performed well, with the chemical ETF achieving four consecutive daily gains, reaching its highest point since January 2022 [21][23] AI and Technology Impact - China's AI token usage surpassed that of the US for the first time, indicating a potential benefit for domestic computing power [21][29] - The cloud computing sector is entering a price increase cycle, with the big data ETF seeing a significant price increase [21][29] Electricity Sector - The electricity sector experienced a strong rally, with the electricity ETF rising by 2.64%, reaching a new high since its listing [2][26] - The demand for electricity is expected to increase due to the growth of AI, making it a defensive investment in the current market environment [2][29] Medical Sector - The largest medical ETF in the market saw a price increase of 1.14%, recovering its annual line, with significant net subscriptions in the previous days [2][29] - The medical sector is expected to benefit from the growth of the CXO model, with strong performance from companies like WuXi AppTec [12][29] Investment Recommendations - Focus on cyclical commodities such as chemicals, non-ferrous metals, and agricultural products, as well as sectors related to technology and national strength, such as military and new energy [22] - The medical sector is recommended for investment, particularly in areas like AI healthcare and medical devices, which are expected to see significant growth [15][16]